{"id":"W4392384788","doi":"10.1016/j.esmoop.2024.102388","title":"Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Aptitude Health; Oncolytics Biotech; Seagen; Puma Biotechnology; Daiichi-Sankyo; Genentech; Veracyte; Pfizer; Incyte; Queen Mary University of London; Clovis Oncology; Astellas Pharma; Eisai; Jazz Pharmaceuticals; National Institutes of Health; Natera; Baxalta; Amgen; Ariad Pharmaceuticals; National Cancer Institute; Servier; Gilead Sciences; Exelixis; Sanofi; GlaxoSmithKline; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Les Laboratories Pierre Fabre","keywords":"Breast cancer; Medicine; Hazard ratio; Internal medicine; Oncology; Confidence interval; Proportional hazards model; Trastuzumab; Cohort; Regimen; Human Epidermal Growth Factor Receptor 2; Stage (stratigraphy); Clinical endpoint; Survival analysis; Cancer; Clinical trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002229365,0.0002583025,0.0006953488,0.0002701992,0.00005345932,0.00005505788,0.0006391454,0.00009244359,0.00007118291],"category_scores_gemma":[0.00001061001,0.0001964179,0.0002084848,0.002683648,0.0001557078,0.00002152759,0.0004591585,0.0001262869,0.000001778629],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001204531,"about_ca_system_score_gemma":0.0001577612,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.2216481,"about_ca_topic_score_gemma":0.1605046,"domain_scores_codex":[0.9980924,0.0002796734,0.0004565683,0.0005822121,0.000262466,0.0003266832],"domain_scores_gemma":[0.9989817,0.0001017898,0.00019384,0.0005336978,0.0001419075,0.00004708785],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003281062,0.000283738,0.9754258,0.00004538747,0.00889548,0.00002192243,0.0008608301,0.01202615,0.00003026416,0.0000386178,0.0009870649,0.0010566],"study_design_scores_gemma":[0.000623016,0.0001039955,0.9943213,0.0001349228,0.003182719,0.000002591265,0.0003154786,0.000577593,0.0001199436,0.000008158012,0.0004231881,0.000187131],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9705813,0.000947043,0.00001595629,0.000343308,0.00006286084,0.0007192114,0.02716544,0.000003908009,0.0001609593],"genre_scores_gemma":[0.991734,0.0005388857,0.00004188928,0.0001361579,0.00004790184,0.0002429599,0.007212501,0.00001857103,0.00002713172],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06114351,"threshold_uncertainty_score":0.854814,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01337270380704992,"score_gpt":0.3078393079096106,"score_spread":0.2944666041025606,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}